CD1D and neoplasm: Arming iNKT cells with CAR may provide a potent anti-tumor therapy that can remediate the tumor microenvironment (TME) through simultaneous depletion of TAMs and tumor cells using TCR/CD1d and CAR recognition, respectively, as well as generalized elimination of both via NK receptors.